Open Access 01-12-2012 | Case report
Intraarticular hemorrhage due to bevacizumab in a patient with metastatic colorectal cancer: a case report
Published in: Journal of Medical Case Reports | Issue 1/2012
Login to get accessAbstract
Introduction
Bevacizumab is a monoclonal antibody against vascular endothelial growth factor. It is widely used in the treatment of metastatic colorectal cancer. It has some specific side effects including severe bleeding, wound healing problems, gastrointestinal perforation, proteinuria and hypertension.
Case presentation
We present the case of a 65-year old Asian man with synovial metastasis of the knee who experienced intraarticular hemorrhage after bevacizumab treatment. He presented with monoarthritis of the left knee.
Conclusion
Bevacizumab-related hemorrhage can cause serious morbidity and unusual sites of hemorrhage may be seen.